 |
|
|
| |
Sustained Virologic Response in Chronic HCV Genotype (GT) 1-Infected Null Responders With Combination of Daclatasvir (DCV; NS5A Inhibitor) and Asunaprevir (ASV; NS3 Inhibitor[protease]) With or Without Peginterferon Alfa-2a/Ribavirin (PEG/RBV)....and triple all-oral Daclatasvir+Asunaprevir+Rbv (gt1a/1b)
|
| |
| |
Reported by Jules Levin
APASL Liver Week 2013: The 2013 Annual Meeting of the
Asian Pacific Association for the Study of the Liver
Singapore, June 6-10, 2013
EASL: Interim Analysis of an Interferon (IFN)- and Ribavirin (RBV)-Free Regimen of Daclatasvir (DCV), Asunaprevir (ASV), and BMS-791325 in Treatment-Naive, Hepatitis C Virus Genotype 1-Infected Patients - (04/25/13)
Lok AS, Gardiner DF, Hezode C, Lawitz EJ, Bourliere M, Everson GT, Marcellin P, Rodriguez-Torres M, Pol S, Serfaty L, Eley T, Huang S-P, Wind-Rotolo M, McPhee F, Grasela DM, and Pasquinelli C
|
| |
|
|
|
|
|
